8-KOther Events

BRISTOL MYERS SQUIBB CO 8-K Report (Nov 30, 2001)

Filed November 30, 2001For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) announced the completion of the sale of its Clairol beauty care business to Procter & Gamble (P&G) for $4.95 billion in cash. This strategic divestiture, finalized on November 15, 2001, is a significant move for BMY, allowing the company to streamline its operations and focus on its core pharmaceutical and healthcare businesses. The substantial cash infusion from this sale will provide BMY with considerable financial flexibility for future investments, research and development, or debt reduction. The company has clearly communicated that Clairol was treated as a discontinued operation in its recent financial reporting, simplifying the presentation of financial results going forward. Investors should note that the substantial gain realized from this sale will impact future earnings reports, although the exact timing and magnitude of its recognition will depend on accounting standards and the company's reporting practices. This transaction marks a strategic shift for BMY, signaling a commitment to enhancing shareholder value through a more focused business strategy.

Key Highlights

  • 1Bristol-Myers Squibb completed the sale of its Clairol beauty care business to Procter & Gamble on November 15, 2001.
  • 2The sale generated $4.95 billion in cash proceeds for Bristol-Myers Squibb.
  • 3The transaction was conducted at arm's length, indicating a fair market valuation.
  • 4Clairol has been classified as a discontinued operation in BMY's financial statements for the year ended December 31, 2000, and the nine months ended September 30, 2001.
  • 5The pro forma balance sheet indicates the use of $1.574 billion of the proceeds to repay commercial paper, reducing short-term borrowings.
  • 6An estimated gain on the sale of approximately $4.2 billion is reported, subject to adjustments and taxes.
  • 7This divestiture represents a strategic refocusing of Bristol-Myers Squibb towards its core pharmaceutical and healthcare segments.

Frequently Asked Questions

This 8-K filing serves to report the completion of a significant corporate event: the sale of Bristol-Myers Squibb's Clairol beauty care business to Procter & Gamble for $4.95 billion in cash.

The $4.95 billion in cash proceeds will significantly strengthen BMY's balance sheet. The filing indicates an immediate use of $1.574 billion to pay down commercial paper. The remaining proceeds provide substantial liquidity for strategic investments, debt repayment, or other corporate purposes, enhancing financial flexibility.

The company estimates a pre-tax gain of approximately $4.2 billion from the sale of Clairol. This gain, after accounting for estimated taxes, will impact future reported earnings. Since Clairol was already presented as a discontinued operation, the current and prior periods' results are cleaner, and the gain will be recognized as a discrete item.

Pro forma statements of earnings were not included because Clairol was already presented as a discontinued operation in prior filings (10-K for FY2000 and 10-Q for 9/30/2001), as permitted by Regulation S-X. However, an unaudited pro forma balance sheet is provided for illustrative purposes to show the financial position adjusted for the divestiture.